{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T19:52:09Z","timestamp":1794340329137,"version":"4.9.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,9,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Outcome after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is adversely affected by relapse to a considerable degree. To exploit the graft-versus-leukemia effect more effectively, we assessed the feasibility of early initiation of epigenetic therapy with panobinostat and decitabine after allo-HSCT and before donor lymphocyte infusion (DLI) in poor-risk patients with acute myeloid leukemia (AML) or refractory anemia with excess blasts with International Prognostic Scoring System score \u22651.5. A total of 140 poor-risk patients with AML aged 18 to 70 years were registered, and 110 proceeded to allo-HSCT. Three dose levels were evaluated for dose-limiting toxicities, including panobinostat monotherapy 20 mg at days 1, 4, 8, and 11 of a 4-week cycle (PNB mono group) and panobinostat combined with either decitabine 20 mg\/m2 (PNB\/DAC20 group) or decitabine 10 mg\/m2 (PNB\/DAC10 group) at days 1 to 3 of every 4-week cycle. After phase 1, the study continued as phase 2, focusing on completion of protocol treatment and treatment outcome. PNB mono and PNB\/DAC10 were feasible, whereas PNB\/DAC20 was not related to prolonged cytopenia. Sixty of 110 patients who underwent transplantation were eligible to receive their first DLI within 115 days after allo-HSCT. Grade 3 and 4 adverse events related to panobinostat and decitabine were observed in 23 (26%) of the 87 patients, and they received epigenetic therapy. Cumulative incidence of relapse was 35% (standard error [SE] 5), and overall survival and progression-free survival at 24 months were 50% (SE 5) and 49% (SE 5). Post\u2013allo-HSCT epigenetic therapy with panobinostat alone or in combination with low-dose decitabine is feasible and is associated with a relatively low relapse rate. The trial was registered at the European Clinical Trial Registry, https:\/\/www.clinicaltrialsregister.eu, as ECT2012-003344-74.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020002074","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T17:36:31Z","timestamp":1600277791000},"page":"4430-4437","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":29,"title":["Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation"],"prefix":"10.1182","volume":"4","author":[{"given":"Burak","family":"Kalin","sequence":"first","affiliation":[{"name":"Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"van Norden","sequence":"additional","affiliation":[{"name":"HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"van Gelder","sequence":"additional","affiliation":[{"name":"Department of Hematology, Maastricht University Medical Center, Maastricht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Breems","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Network Antwerp, Campus Stuivenberg, Antwerp, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital Gasthuisberg, KU Leuven, Leuven, Belgium; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojca","family":"Jongen-Lavrencic","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annoek E. C.","family":"Broers","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Braakman","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Grob","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendelien","family":"Zeijlemaker","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert J.","family":"Ossenkoppele","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Meijer","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Cornelissen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,9,16]]},"reference":[{"issue":"4","key":"2020091611382413100_B1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2020091611382413100_B2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic stem cell transplantation for patients with AML in first complete remission","volume":"127","author":"Cornelissen","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2020091611382413100_B3","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2009.813","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials","volume":"301","author":"Koreth","year":"2009","journal-title":"JAMA"},{"key":"2020091611382413100_B4","article-title":"Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete Remission","volume":"1","author":"Versluis","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"17","key":"2020091611382413100_B5","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1200\/JCO.2011.39.6499","article-title":"Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories","volume":"30","author":"Cornelissen","year":"2012","journal-title":"J Clin Oncol"},{"issue":"23","key":"2020091611382413100_B6","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1002\/cncr.25500","article-title":"Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study","volume":"116","author":"de Lima","year":"2010","journal-title":"Cancer"},{"issue":"2","key":"2020091611382413100_B7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.bbmt.2015.09.004","article-title":"Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial","volume":"22","author":"Craddock","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2020091611382413100_B8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-015-0208-3","article-title":"Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome","volume":"8","author":"Han","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"10","key":"2020091611382413100_B9","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.bbmt.2015.05.026","article-title":"Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome","volume":"21","author":"Pusic","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2020091611382413100_B10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/leu.2011.234","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leukemia"},{"issue":"21","key":"2020091611382413100_B11","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.5884.5884","article-title":"Azacitidine maintenance after allogeneic stem cell transplantation is feasible in patients with acute myeloid leukemia and myelodysplasia [abstract]","volume":"124","author":"Antar","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2020091611382413100_B12","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1038\/leu.2017.242","article-title":"Phase I\/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)","volume":"31","author":"Bug","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"2020091611382413100_B13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/5047","article-title":"Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer","volume":"21","author":"Cameron","year":"1999","journal-title":"Nat Genet"},{"issue":"4","key":"2020091611382413100_B14","first-page":"1327","article-title":"DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors","volume":"61","author":"Zhu","year":"2001","journal-title":"Cancer Res"},{"issue":"17","key":"2020091611382413100_B15","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1038\/sj.onc.1205376","article-title":"Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors","volume":"21","author":"Kikuchi","year":"2002","journal-title":"Oncogene"},{"issue":"3","key":"2020091611382413100_B16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2174\/1568011033482440","article-title":"The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells","volume":"3","author":"Zhu","year":"2003","journal-title":"Curr Med Chem Anticancer Agents"},{"issue":"2","key":"2020091611382413100_B17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.13016","article-title":"A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome","volume":"167","author":"Kirschbaum","year":"2014","journal-title":"Br J Haematol"},{"issue":"10","key":"2020091611382413100_B18","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.3109\/10428194.2015.1018248","article-title":"A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia","volume":"56","author":"How","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2020091611382413100_B19","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood-2006-03-009142","article-title":"Phase 1\/2 study of the combination of 5-aza-2\u2032-deoxycytidine with valproic acid in patients with leukemia","volume":"108","author":"Garcia-Manero","year":"2006","journal-title":"Blood"},{"issue":"31","key":"2020091611382413100_B20","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1200\/JCO.2012.45.9628","article-title":"High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study","volume":"31","author":"Terwijn","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020091611382413100_B21","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1751-553X.2012.01416.x","article-title":"Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia","volume":"34","author":"Terwijn","year":"2012","journal-title":"Int J Lab Hematol"},{"key":"2020091611382413100_B22","year":"2009"},{"key":"2020091611382413100_B23","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9134","key":"2020091611382413100_B24","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","article-title":"Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation","volume":"352","author":"Gratwohl","year":"1998","journal-title":"Lancet"},{"issue":"16","key":"2020091611382413100_B25","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","article-title":"High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease","volume":"115","author":"Luznik","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2020091611382413100_B26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","article-title":"Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning","volume":"19","author":"Raiola","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020091611382413100_B27","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2020091611382413100_B28","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"2020091611382413100_B29","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.bbmt.2012.07.003","article-title":"Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation","volume":"18","author":"Ciurea","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2020091611382413100_B30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-018-0586-4","article-title":"Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT","volume":"11","author":"Ruggeri","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"1-3","key":"2020091611382413100_B31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12026-009-8139-0","article-title":"High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation","volume":"47","author":"Luznik","year":"2010","journal-title":"Immunol Res"},{"issue":"31","key":"2020091611382413100_B32","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1200\/JCO.2013.54.0625","article-title":"Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning","volume":"32","author":"Kanakry","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020091611382413100_B33","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.bbmt.2016.05.010","article-title":"Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia: A Retrospective Single-Center Review","volume":"22","author":"Rashidi","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"2020091611382413100_B34","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2014-07-587477","article-title":"Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS","volume":"124","author":"Kanakry","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2020091611382413100_B35","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","article-title":"Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation","volume":"108","author":"Schmid","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2020091611382413100_B36","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/bmt.2011.15","article-title":"Early allo-SCT for AML with a complex aberrant karyotype\u2013results from a prospective pilot study","volume":"47","author":"Schmid","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2020091611382413100_B37","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1080\/10428190701471981","article-title":"Decitabine and its role in the treatment of hematopoietic malignancies","volume":"48","author":"Plimack","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"2020091611382413100_B38","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0065-230X(08)60703-4","article-title":"Ara-C: cellular and molecular pharmacology","volume":"72","author":"Grant","year":"1998","journal-title":"Adv Cancer Res"},{"issue":"34","key":"2020091611382413100_B39","doi-asserted-by":"crossref","first-page":"56802","DOI":"10.18632\/oncotarget.18063","article-title":"Decitabine inhibits T cell proliferation via a novel TET2-dependent mechanism and exerts potent protective effect in mouse auto- and allo-immunity models","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"2020091611382413100_B40","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3389\/fimmu.2018.00617","article-title":"Decitabine Inhibits Gamma Delta T Cell Cytotoxicity by Promoting KIR2DL2\/3 Expression","volume":"9","author":"Niu","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"2020091611382413100_B41","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/imm.12261","article-title":"Impact of 5-aza-2\u2032-deoxycytidine and epigallocatechin-3-gallate for induction of human regulatory T cells","volume":"142","author":"Kehrmann","year":"2014","journal-title":"Immunology"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/18\/4430\/1758388\/advancesadv2020002074.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/18\/4430\/1758388\/advancesadv2020002074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T17:38:21Z","timestamp":1600277901000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/18\/4430\/463761\/Panobinostat-and-decitabine-prior-to-donor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":41,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2020,9,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020002074","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,16]]}}}